Shattuck Labs(STTK) - 2025 Q4 - Annual Report

Drug Development and Clinical Trials - SL-325 is a high-affinity DR3 blocking monoclonal antibody expected to achieve best-in-class clinical remission rates in patients with inflammatory bowel disease (IBD) due to a more complete blockade of the DR3/TL1A pathway[21]. - The ongoing Phase 1 clinical trial for SL-325 in healthy volunteers is expected to be completed in Q2 2026, with a Phase 2 trial in Crohn's Disease patients anticipated to start in Q3 2026[21][30]. - SL-325 is currently being evaluated in a Phase 1 clinical trial with approximately 72 healthy volunteers, assessing safety, tolerability, and pharmacokinetics[58]. - The company plans to initiate a Phase 2 clinical trial in patients with Crohn's disease in the third quarter of 2026, evaluating two dose levels of SL-325 versus placebo[62]. - The ongoing chronic GLP toxicology study of SL-325 is expected to be completed in the first quarter of 2026, with favorable immunogenicity profiles observed so far[56]. - The approval process for clinical trials varies widely by country, affecting the timeline and potential pricing of products[158]. - The process for obtaining regulatory approvals involves multiple stages, including preclinical tests, IND submission, and clinical trials[86]. - Clinical trials are conducted in three phases, with Phase 3 trials aimed at establishing the overall risk/benefit ratio for product approval[91]. Market Potential and Competition - The IBD market is projected to grow from $23 billion in 2023 to $34 billion by 2030, highlighting the commercial potential for SL-325 and related therapies[38]. - The clinical success of TL1A blocking antibodies has shown placebo-adjusted clinical remission rates of 23-28% in patients with UC, indicating a significant market opportunity for SL-325 if it surpasses these rates[36]. - The company faces competition from clinical-stage therapeutics targeting the TL1A/DR3 axis, including candidates from Teva, Abbvie, and Merck[72]. - Competitors possess greater financial resources and expertise in R&D, manufacturing, and regulatory approvals, which may impact the company's market position[73]. - The company’s commercial opportunity could diminish if competitors develop safer, more effective, or less expensive products[74]. Regulatory Environment - The FDA requires extensive data demonstrating the quality, safety, and efficacy of new therapeutic products before they can be marketed[84]. - The FDA may require additional clinical trials post-approval, known as Phase 4 studies, to gather more information about the product[92]. - A BLA submission must include all relevant data from preclinical and clinical studies, including negative results, and requires a substantial application user fee[94]. - The FDA aims to review standard BLAs within ten months and priority reviews within six months after filing[96]. - The FDA may issue an approval letter or a Complete Response letter after evaluating a BLA, detailing any deficiencies found[99]. - The company must navigate complex regulatory requirements, which require substantial time and financial resources[86]. - The FDA requires manufacturers to perform tests on each lot of biological products before distribution, ensuring compliance with safety, purity, and potency standards[112]. Intellectual Property - The company holds two issued U.S. patents and has four pending international patent applications related to its key technologies as of February 20, 2026[82]. - The patent term for most countries is 20 years from the application filing date, with potential extensions available under U.S. law[80]. - The BPCIA allows for a five-year patent extension post-BLA approval, with a maximum total patent term of 14 years from product licensure[123]. Safety and Efficacy - SL-325's favorable safety profile is supported by non-human primate studies showing no toxicity and durable receptor occupancy for at least two months[22][30]. - SL-325 specifically binds to human DR3 with a 1.3 picomolar affinity and demonstrates a slow off-rate, suggesting durable binding in vivo[46]. - In preclinical studies, SL-325 maintained full DR3 receptor occupancy (RO) at doses of 1 mg/kg or higher within two hours of infusion, lasting throughout a 14-day inter-dose interval[50]. - The No Observed Adverse Effect Level from the GLP toxicology study was determined to be 100 mg/kg, with no infusion-related reactions or organ dysfunction observed[50]. - SL-325 was designed to avoid immune complex formation, which is a common issue with TL1A blocking antibodies, potentially leading to a better immunogenicity profile[43]. Compliance and Legal Considerations - Compliance with healthcare laws, such as the Anti-Kickback Statute and the False Claims Act, is critical to avoid significant penalties and reputational harm[125][127]. - The company faces significant uncertainty regarding the coverage and reimbursement status of any pharmaceutical or biological product for which it obtains regulatory approval[142]. - The company must provide scientific and clinical support for the use of its product candidates to each payor separately, with no assurance of consistent coverage and adequate reimbursement[143]. - The company is subject to evolving regulations regarding the use of artificial intelligence and machine learning, particularly concerning data bias and anti-discrimination[140]. International Regulations - Approval from foreign regulatory authorities is required before commencing clinical trials or marketing products in those countries, similar to the FDA process[157]. - The centralized authorization procedure allows for a single marketing authorization valid across all EU Member States, with a typical evaluation timeframe of 210 days[178]. - The European General Data Protection Regulation (GDPR) imposes strict obligations on the processing of personal data, including health-related data, with potential fines of up to €20 million or 4% of total worldwide annual turnover for noncompliance[165]. - The holder of a MA must adhere to EU pharmacovigilance legislation, ensuring ongoing safety assessment of medicinal products[205].